Page last updated: 2024-09-05

avasimibe and Apolipoprotein B-100, Familial Defective

avasimibe has been researched along with Apolipoprotein B-100, Familial Defective in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ	1

Trials

1 trial(s) available for avasimibe and Apolipoprotein B-100, Familial Defective

Article	Year
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis, 2003, Volume: 171, Issue:2 Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome	2003

Article

Year

Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.

Atherosclerosis, 2003, Volume: 171, Issue:2

Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome

2003